Cardiac Hypertrophy

2

Review clinical trials related to Cardiac Hypertrophy. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia

The purpose of this study is to test the safety and preliminary efficacy of AAVrh.10hFXN to treat the cardiomyopathy associated with Friedreich's ataxia (FA). AAVrh.10hFXN is a serotype rh.10 adeno-associated virus gene transfer vector coding for Frataxin (FXN). The drug is administered intravenously. This is a phase 1, open label, dose escalation study with a total of 25 participants.

Participants needed: 25
Trial details
Phase: Phase 1Age: 12-50Biological sex: AllType: InterventionalSponsor: Weill Medical College of Cornell UniversityUpdated: Mar 31, 2026Locations: 1
Eligibility criteria

Males and females, age 12 to 50 [+24]

Individuals receiving corticosteroids or other immunosuppressive medications [+22]

Status: Recruiting

Fish Oil, Metformin and Heart Health in PCOS

Women with Polycystic Ovary Syndrome (PCOS) have high testosterone levels which is associated with altered insulin-glucose metabolism and an adverse blood lipid profile, predisposing them to the development of Type II Diabetes and Cardiovascular Disease (CVD). This study will investigate the use of dietary fish oil supplementation as a safe and effective intervention, and as an adjunct therapy to standard of care treatment with metformin to improve heart health, blood lipids and insulin-glucose metabolism in women with PCOS, and those with PCOS and Type 2 Diabetes.

Participants needed: 146
Trial details
Phase: Phase 1Age: 25-45Biological sex: FemaleType: InterventionalSponsor: University of AlbertaUpdated: Dec 12, 2025Locations: 3
Eligibility criteria

diagnosis of PCOS [+4]